House Oversight Hearing Showcases Harrowing Whistleblower Accounts and Calls to Rework OPO Oversight
Loading...
Summary
Witnesses at a House Ways and Means oversight hearing described cases of missed donor screening, coerced consent and a CMS accounting loophole that may have led to thousands of pancreases being recovered but not used; lawmakers pressed HHS, CMS and HRSA for faster decertification and greater transparency.
WASHINGTON — Lawmakers pressed federal health officials on Wednesday to act quickly after witnesses described practices at some organ procurement organizations (OPOs) that they said put patients and donor families at risk and distorted performance metrics.
The House Ways and Means Oversight Subcommittee heard testimony from a recipient family, former OPO staff and outside experts who described cases in which organs were recovered despite later findings of donor disease, alleged coerced consent of grieving families and a regulatory loophole that has allowed OPOs to count organs recovered for “research” toward performance metrics.
The hearing focused on individual harm and systemic incentives. ‘‘Our prayers were answered on 10/29/2022 when a donor match was found,’’ witness Heather Hollis Knuckles said of her mother’s transplant; five days after surgery, Barnes Hospital pathology told her family the donor liver contained high‑grade metastatic cancer and her mother died weeks later. Knuckles asked the committee to use its oversight powers to investigate donor‑screening failures and ensure recipients are safe.
Former OPO preservationist Nikki Martin described workplace pressure and retaliation after raising concerns, including what she characterized as a case where a patient briefly regained consciousness and staff were told to “handle it internally.” ‘‘We were silenced,’’ Martin said, urging Congress to strengthen whistleblower protections and remove dangerous contractors.
Jennifer Erickson, senior fellow for organ donation policy at the Federation of American Scientists, told the committee that agencies and investigators have documented cases of misuse of donor organs and taxpayer funds. Erickson cited a 2020 CMS rule change that she said let OPOs record recovered pancreases as ‘‘research’’ and said her team’s review found ‘‘over 7,000’’ pancreases recovered nationwide since 2020 with little evidence they were used for research. She said the pattern can artificially inflate performance metrics and keep underperforming OPOs in place.
‘‘These things are crimes,’’ Erickson said, calling on HHS, CMS, state attorneys general and the Department of Justice to pursue cases where fraud or unlawful conduct is indicated. She also urged CMS to use its existing authority to decertify contractors that fail to meet requirements.
Witnesses and members also discussed financial flows and transparency. Committee members cited reports that OPOs have transferred large sums to related organizations and urged greater public disclosure of Medicare cost reports and OPO performance data. Representative Carol Miller and others pressed for data that distinguishes clinically usable recoveries from recoveries counted for financial purposes.
Experts at the hearing warned lawmakers that separate but related policy choices — notably potential cuts to premium tax credits and other changes to health coverage — could worsen transplant access because many transplant centers require stable insurance for listing and post‑transplant care. Emily Gee of the Center for American Progress told the subcommittee that reductions in coverage would likely reduce the number of patients eligible for transplantation and complicate follow‑up care.
Members pressed for a mix of administrative and legislative remedies: immediate use of CMS decertification authority where evidence warrants it, closing the ‘‘research’’ accounting loophole, publishing more granular OPO data for public and agency scrutiny, and strengthening whistleblower protections. No formal votes were taken at the hearing; members said they would submit follow‑up questions and consider legislative options.
The subcommittee’s oversight letters and prior HRSA and inspector general reviews were cited repeatedly; witnesses urged coordination with state and federal law enforcement where evidence of criminal conduct exists. The committee adjourned after members said they would collect additional documents and submit written questions to witnesses.
(Reporting by the House Ways and Means Oversight Subcommittee hearing record.)
